ArticleBiochemistry and biophysics reports2025
Construction and validation of a post-translational modification-related signature to predict the effect of immune therapies in gastric cancer.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a highly heterogeneous malignancy of the digestive system. Treatment outcomes and prognosis for GC vary significantly depending on the molecular subtype. Protein posttranslational modifications (PTMs), including Ubiquitination, SUMOylation, and NEDDylation, have been implicated in the emergence and progression of GC, though the precise mechanisms remain unclear. Therefore, it is critical to elucidate the prognosis and treatment role of PTM-related genes (PRGs) in GC by Cox regression and clustering analysis. In this study, we utilized PRGs to classify GC into three molecular subtypes. Using LASSO and Cox regression analyses, we developed a PTM-related prognostic signature consisting of six prognostic PRGs in the TCGA-STAD cohort, and we validated this signature in the independent GSE62254 dataset. The resulting risk score has the ability to forecast the overall survival (OS) in GC patients. This signature stratifies patients into high- and low-risk groups with significantly different OS outcomes (p < 0.001). Notably, lower risk scores correlate with higher tumor mutation burden (TMB) values, lower TIDE scores, higher MSI-H ratios, and better responses to immunotherapy. Collectively, our results provide a basis for PTM-related research and construct a prognostic signature for GC. This signature holds promise for advancing diagnostic strategies and enhancing therapeutic approches in GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.